Fubotv earnings beat by $0.10, revenue topped estimates
Director Richard J Hawkins (NASDAQ:HWKN) of Savara Inc (NASDAQ:SVRA), a $441 million market cap biotechnology company, acquired 48,225 shares of common stock on June 20, 2025, according to a Form 4 filing with the Securities and Exchange Commission.
The shares were purchased at a weighted average price of $2.044, for a total transaction value of $98,571. The prices for the purchases ranged from $2.0345 to $2.045
In other recent news, Savara Inc. announced its first-quarter 2025 results and corporate updates, including a Refusal to File (RTF) from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) for Molbreevi. The FDA requested additional Chemistry, Manufacturing, and Controls (CMC) data, although no further efficacy trials were suggested. Savara plans to submit its Marketing Authorization Application (MAA) for Molbreevi in Europe and the UK by the end of 2025. Analysts from Oppenheimer assumed coverage of Savara with an Outperform rating and a $5 price target, while H.C. Wainwright downgraded the stock to Neutral with a $2 price target, citing concerns over communication with investors and the FDA. Guggenheim maintained a Buy rating but adjusted the price target to $8, reflecting a delayed market launch of Molbreevi. Evercore ISI also revised its price target to $2, maintaining an In Line rating due to anticipated challenges with the BLA. The firm’s analysts anticipate a potential commercial launch in January 2027, contingent on future regulatory approvals. Savara’s efforts to address regulatory requirements for Molbreevi continue to be a focal point for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.